China Resources Sanjiu Medical & Pharmaceutical (SHE:000999) recorded an 18% rise in attributable profit for 2024 to 3.37 billion yuan from 2.85 billion yuan a year prior, a Wednesday filing by parent China Resources Pharmaceutical Group (HKG:3320) with the Hong Kong bourse said.
Earnings per share were 2.63 yuan in the year, up from 2.23 yuan in the last fiscal year.
The drug company's revenue rose by 12% to 27.6 billion yuan in the period from 24.7 billion yuan a year prior.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。